Want to see IMUX full AI Analyst Report?
IMUX Stock Chart & Stats
$13.39
$0.34(2.54%)
At close: 4:00 PM EDT
$13.39
$0.34(2.54%)
Day’s Range― - ―
52-Week Range$5.06 - $16.86
Previous CloseN/A
Volume44.90K
Average Volume (3M)172.86K
Market Cap
$217.36M
Enterprise Value$498.91
Total Cash (Recent Filing)$155.10M
Total Debt (Recent Filing)$567.00K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Oct 29, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.80
Shares Outstanding13,644,467
10 Day Avg. Volume173,429
30 Day Avg. Volume172,859
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.50Price Target Upside180.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Commercial And Regulatory LeadershipAdding a leader with proven MS commercialization experience and a veteran board chair materially strengthens Immunic’s ability to plan regulatory strategy, design launch infrastructure, and engage payors and partners. That institutional commercial know-how reduces execution risk entering pivotal/approval stages.
Positive Phase 2 CALLIPER MS Clinical Signal And TolerabilityConsistent phase 2 efficacy signals and a placebo-comparable safety profile across 467 patients support a credible path to pivotal success and regulatory acceptance. Clinically meaningful endpoints and tolerability improve the long-term probability of approval and future commercial differentiation in MS.
Very Low Leverage And Improved TTM EquityNear-zero debt reduces financial distress risk and preserves strategic optionality to execute multi-year clinical programs. The material improvement in TTM equity versus 2025 strengthens the capital structure and gives the company more flexibility to raise non-debt financing or pursue partnerships.
Bears Say
No Revenue And Large Recurring LossesAs a pre-commercial biotech, Immunic has no product revenue and large recurring losses, which will keep operating leverage negative until commercialization. Persistent negative earnings pressure equity, limit reinvestment capacity, and make long-term value creation dependent on successful clinical outcomes.
High Cash Burn And Financing DependenceSustained negative operating and free cash flow create continual dependency on external financing. Regular capital raises can dilute shareholders, constrain strategic choices, and distract management with financing activities rather than purely clinical and commercial execution.
Dilution Risk From Expanded Equity Plan And Continued FinancingExpanding the equity pool and relying on private placements increases the likelihood of future dilution. While stock incentives aid talent retention, a larger authorized share reserve combined with regular financings reduces per-share economics and can erode investor returns absent clear clinical or commercial milestones.
Immunic News
IMUX FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was $5.06 and its highest was $16.86 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is $217.36M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 76 days.
How were Immunic, Inc.’s earnings last quarter?
Immunic, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.165 by $0.365.
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -1.02.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 13,644,467 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Immunic, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.165. Following the earnings report the stock price went up 9.787%.
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.50 (180.06% Upside)
$37.50 (180.06% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 100.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
159.11%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$37.50
▲(180.06% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
6.83% Insiders
8.49% Mutual Funds
14.67% Other Institutional Investors
65.11% Public Companies and
Individual Investors